Libido Reduction with Isotretinoin (Curacne) and Retatrutide
Isotretinoin can cause decreased libido in a subset of patients, with real-world pharmacovigilance data showing statistically significant signals for "decreased libido" (PRR=3.63) and "loss of libido" (PRR=4.56), though the overall evidence suggests this occurs in a minority of users and most studies show neutral or beneficial effects on sexual function.
Evidence Quality and Context
The question asks about isotretinoin (Curacne) specifically—there is no available evidence regarding retatrutide's effects on libido in the provided literature, so this answer focuses solely on isotretinoin.
Key Findings from Pharmacovigilance Data
The most robust signal comes from a 2026 FAERS analysis 1 covering 20 years of adverse event reports:
- "Decreased libido": 76 reports with PRR=3.63 (95% CI 2.89-4.54)
- "Loss of libido": 64 reports with PRR=4.56 (95% CI 3.57-5.84)
- "Sexual dysfunction": Statistically significant disproportionality signal
- These signals indicate isotretinoin is reported more frequently with libido problems than other drugs in the database
Contextualizing the Risk
However, a 2024 comprehensive scoping review 2 of 46 human studies with 2,420 patients found:
- 54% of studies reported beneficial or neutral effects of isotretinoin on sexual function
- The evidence quality was predominantly weak (89% were Oxford level 4 evidence)
- Definitions of sexual dysfunction varied widely across studies, making comparisons difficult
Clinical Implications
The degree of libido reduction appears highly variable and unpredictable:
- Some patients experience significant decreases requiring discontinuation
- Most patients experience no change or improvement (likely due to acne improvement and reduced psychosocial distress)
- A small subset may develop persistent sexual dysfunction even after stopping treatment 3
Specific Considerations
Flutamide (an anti-androgen sometimes used for acne) explicitly lists "decreased libido" as a common side effect 4, but isotretinoin's mechanism differs—it primarily affects sebaceous glands, not hormonal pathways directly.
Depression confounding: The 2016 AAD guidelines 4 note that isotretinoin generally improves mood in acne patients, and depression itself causes decreased libido. The psychiatric symptoms reported in some cases 5 may represent the underlying mechanism for sexual dysfunction rather than a direct drug effect.
Monitoring Recommendations
Before starting isotretinoin:
- Document baseline sexual function and libido
- Screen for depression and relationship issues
- Explain that sexual side effects are possible but uncommon
During treatment:
- Routinely inquire about sexual function at follow-up visits (these symptoms are significantly underreported 1)
- If decreased libido develops, assess for concurrent depression or relationship stressors
- Consider dose reduction or discontinuation if symptoms are severe and clearly temporally related
Important Caveats
- The FAERS data 1 has inherent limitations: underreporting, reporting bias, and inability to establish causation
- The 2024 scoping review 2 concluded there is "very weak evidence supporting a link between isotretinoin and sexual dysfunction"
- Most adverse event reports come from patients already experiencing psychological distress from severe acne
- No standardized definition of "decreased libido" exists across studies, making quantification impossible
Bottom line: While statistically significant pharmacovigilance signals exist, the clinical reality is that most patients do not experience problematic libido reduction, and when it occurs, the degree varies from mild to severe. The lack of prospective, controlled data makes it impossible to predict individual risk or quantify the typical degree of reduction.